The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Relmada expects to initiate its Phase 3 program in the first half of 2026
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Subscribe To Our Newsletter & Stay Updated